The NVAC Pandemic Working Group was created to provide guidance to the Department in an ongoing effort to improve health, social, and economic outcomes in an influenza pandemic through planning and preparedness. In April 2005, a two-day meeting was convened. The primary objects of the first day�s proceedings were:
The second day of the meeting began the work of the Vaccine and Antiviral Subgroups. The morning session was a joint
session where issues relevant to both subgroups will be discussed. These included experiences from past pandemics,
roles of vaccine and antiviral agents in the Draft HHS Pandemic Influenza Preparedness and Response Plan
(http://www.hhs.gov/nvpo/pandemicplan/index.html), and
potential target groups and population sizes. The subgroups then separated and discussed issues unique to their focus.
Additional meetings of the subgroups are being planned and initial reports of the Antiviral and Vaccine Subgroups'
deliberations are planned for presentation at the June NVAC and ACIP meetings, respectively.
|
Tuesday, April 19, 2005
|
| 9:00 am | Welcome | Bruce Gellin (NVPO) |
| 9:15 am | Introductions of working group members | Alan Hinman (NVAC) |
| 9:30 am | Roles and responsibilities | Ben Schwartz (NVPO) |
| 10:00 am | Update on avian influenza | Scott Harper (CDC) |
| 10:30 am | - Break - | |
| 10:45 am | HHS pandemic planning and preparedness activities | Ben Schwartz (NVPO) |
| 11:15 am | CDC pandemic planning and preparedness activities | Rich Schieber (FDA) |
| 11:45 am | NIH pandemic preparedness activities | Linda Lambert (NIH)
Walla Dempsey (NIH) |
| 12:15 pm | FDA pandemic preparedness activities | Sara Gagnetan (FDA)
Barbara Styrt (FDA) |
| 12:30 pm | VA pandemic preparedness activities | Victoria Davey (VA) |
| 12:45 pm | - Lunch - | |
| 1:30 pm | HRSA pandemic preparedness activities | Laura McNally (HRSA) |
| 1:45 pm | Preparedness by stakeholder organizations | Andrew Pavia (IDSA)
Matt Cartter (CSTE)
Richard Raymond (ASTHO) |
| 2:30 pm | Introduction to vaccine and antiviral decision issues | Ben Schwartz (NVPO) |
| 3:15 pm | Canadian pandemic preparedness plan | Theresa Tam (PHAC) |
| 3:45 pm | - Break - |
| 4:00 pm | Health care preparedness and response issues | Patricia Simone (CDC) |
| 4:30 pm | Discussion of Working Group focus and activities | Alan Hinman (NVAC) |
| 5:00 pm | Subgroups and next steps | Alan Hinman (NVAC) |
| |
|
Wednesday, April 20, 2005
|
| 9:00 am |
Background to the NVAC Pandemic Influenza Working Group
and the Vaccine and Antiviral Subgroups
-
Charge to the group, objectives, and timeline
|
Ben Schwartz (NVPO) |
| 9:15 am |
Background on influenza pandemics
- Magnitudes and impacts � brief overview
- Risk groups
- What further information is needed?
- Description of vaccination programs from prior pandemics
|
David Shay (CDC) |
| 10:00 am |
Draft HHS Pandemic Influenza Preparedness and Response Plan
- Pandemic response goals
- Role of vaccination
- Role of antiviral drugs
|
Ben Schwartz (NVPO) |
| 10:30 am | - Break - | |
| 10:45 am |
Potential vaccine target groups and population sizes
- Health care worker strata
- Public safety worker strata
- Essential community service provider strata
- Sanitation
- Mortuary
- Others
| Elizabeth Falcone (NVPO) |
| 11:15 am |
Stratification of risk groups for severe disease |
Guillermo Herrera (CDC) |
| 11:30 am |
Ethics and values |
Kathy Kinlaw (Emory) |
| 12:00 pm |
- Lunch - |
|
| |
|
Breakout session of the Antiviral Sub-group
|
| 1:00 pm |
Background on influenza antiviral drugs
- Types of drug
- Indications for use
|
David Shay (CDC) |
| 1:30 pm |
Antiviral drug impacts and drug resistance |
Fred Hayden (UVA) |
| 2:00 pm |
Antiviral drugs for high-risk populations |
Janet Englund (UW) |
| 2:15 pm |
Oseltamivir production, supply, and cost |
Mike McGuire (Roche) |
| 2:45 pm |
Potential antiviral drug strategies |
Ben Schwartz (NVPO) |
| 3:15 pm |
- Break - |
|
| 3:30 pm |
Antiviral drug strategies in the Canadian plan |
Jill Sciberras (PHAC) |
| 4:00 pm |
Considerations in developing priority group recommendations
- Ethics and values
- Public input
- Economic impacts
- Indirect effects (e.g., on transmission)
- Uncertainty and range of pandemic scenarios
- Other
|
Robert Levine (Yale)
Sarah Landry (NVPO)
Martin Meltzer (UMich)
Fred Hayden (UVA)
|
| 5:00 � 5:15 |
Next steps
- Working groups
- Next meeting
|
Andrew Pavia (IDSA) |
| |
|
Breakout session of the Vaccine Sub-group
|
| 1:00 pm |
Vaccine priority groups in the Canadian Pandemic Plan
and ethical considerations
|
Theresa Tam (PHAC) |
| 1:30 pm |
Vaccine supply and schedule
- Pandemic vaccine supply and timelines
- Current status
- Potential expansion through capacity increase and antigen-sparing
|
Ray Strikas (CDC) |
| 2:00 pm |
Vaccine effectiveness considerations
- By age and risk group for annual vaccine
- Special considerations for pandemic vaccines
- 1 versus 2 doses
- Live versus inactivated vaccines
|
Carolyn Bridges (CDC) |
| 2:30 pm |
- Break - |
|
| 2:45 � 4:00 |
Considerations in developing priority group recommendations
- Public input � VPACE process
- Indirect vaccine effects (e.g., on transmission)
- Uncertainty and range of pandemic scenarios
- Economic impacts
|
Gary Freed (NVAC)
Ban Allos (AMA)
Roger Bernier (CDC)
Arnold Monto (CDC)
Carolyn Bridges (CDC)
Martin Meltzer (UMich)
|
| 4:00 � 4:30 |
Next steps
- Charges to working groups
- Feedback from group regarding how to proceed during second meeting
- Next meeting
|
|
Download Reader 
